For the quarter ending 2025-09-30, VRDN made $187,421K in revenue. -$34,305K in net income. Net profit margin of -18.30%.
| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-09-30 |
|---|---|---|---|---|
| Change in unrealized (loss) gain on investments | - | - | 255 | 1,475 |
| Unrealized gain on available-for-sale securities | 294 | -176 | - | - |
| Total other comprehensive income | 294 | -176 | 255 | 1,475 |
| Total revenue | 70,570 | 75 | 72 | 86 |
| Research and development (including related party expenses of and 4,528 during the three and six months ended june30, 2025, respectively, and 2,551 and 3,212 during the three and six months ended june30, 2024, respectively)-Paragon Therapeutics | - | 0 | - | - |
| Research and development | 86,261 | 86,626 | 76,835 | 69,158 |
| General and administrative | 24,322 | 20,216 | 17,103 | 14,408 |
| Total operating expenses | 110,583 | 106,842 | 93,938 | 83,566 |
| Loss from operations | -40,013 | -106,767 | -93,866 | -83,480 |
| Interest and other income | - | 6,546 | 7,540 | 7,795 |
| Interest income | 5,521 | - | - | - |
| Interest expense | 560 | 514 | 586 | 1,004 |
| Other income (expense), net | 453 | - | - | - |
| Total other income (expense), net | 5,414 | 6,032 | 6,954 | 6,791 |
| Net loss | -34,599 | -100,735 | -86,912 | -76,689 |
| Comprehensive loss | -34,305 | -100,911 | -86,657 | -75,214 |
| Basic eps | - | - | -0.87 | -1.15 |
| Diluted eps | - | - | -0.87 | -1.15 |
| Basic average shares | - | - | 81,344,134 | 66,420,063 |
| Diluted average shares | - | - | 81,344,134 | 66,420,063 |
| Net loss per share, basic (in dollars per share) | -0.34 | - | - | - |
| Net loss per share, diluted (in dollars per share) | -0.34 | - | - | - |
| Weighted-average shares outstanding, basic (in shares) | 81,784,499 | - | - | - |
| Weighted-average shares outstanding, diluted (in shares) | 81,784,499 | - | - | - |
Viridian Therapeutics, Inc. DE (VRDN)
Viridian Therapeutics, Inc. DE (VRDN)